Literature DB >> 15768339

Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.

Steffanie A Strathdee1, M Latka, J Campbell, P T O'Driscoll, E T Golub, F Kapadia, R A Pollini, R S Garfein, D L Thomas, H Hagan.   

Abstract

OBJECTIVE: We sought to identify factors associated with interest in receiving therapy for hepatitis C virus (HCV) infection among HCV-infected injection drug users (IDUs) in 3 United States cities.
METHODS: IDUs aged 18-35 years who were HCV-infected and seronegative for human immunodeficiency virus underwent surveys on behaviors, experience, and interest in treatment for HCV infection and readiness to quit drug use.
RESULTS: Among treatment-naive IDUs (n=216), 81.5% were interested in treatment for HCV infection, but only 27.3% had seen a health-care provider since receiving a diagnosis of HCV infection. Interest in treatment for HCV infection was greater among IDUs with a high perceived threat of progressive liver disease, those with a usual source of care, those without evidence of alcohol dependence, and those with higher readiness scores for quitting drug use. Interest in treatment for HCV infection was 7-fold higher among IDUs who were told by their health-care provider that they were at risk for cirrhosis or liver cancer.
CONCLUSIONS: Improving provider-patient communication and integrating treatments for substance abuse and HCV may increase the proportion of IDUs who initiate treatment for HCV infection.

Entities:  

Mesh:

Year:  2005        PMID: 15768339      PMCID: PMC2196220          DOI: 10.1086/427445

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

Review 1.  Prevention and treatment of hepatitis C in injection drug users.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Management of hepatitis C patients by primary care physicians in the USA: results of a national survey.

Authors:  T M Shehab; S S Sonnad; A S Lok
Journal:  J Viral Hepat       Date:  2001-09       Impact factor: 3.728

3.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

Authors:  D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

4.  Treatment of acute hepatitis C with interferon alfa-2b.

Authors:  E Jaeckel; M Cornberg; H Wedemeyer; T Santantonio; J Mayer; M Zankel; G Pastore; M Dietrich; C Trautwein; M P Manns
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

5.  Trust and the acceptance of and adherence to antiretroviral therapy.

Authors:  F L Altice; F Mostashari; G H Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2001-09-01       Impact factor: 3.731

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Diagnosis and 10-year follow-up of a community-based hepatitis C cohort.

Authors:  Barbara P Yawn; Peter Wollan; Liliana Gazzuola; W Ray Kim
Journal:  J Fam Pract       Date:  2002-02       Impact factor: 0.493

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Treating hepatitis C in methadone maintenance patients: an interim analysis.

Authors:  Diana L Sylvestre
Journal:  Drug Alcohol Depend       Date:  2002-07-01       Impact factor: 4.492

10.  Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.

Authors:  Catherine A Fleming; Donald E Craven; David Thornton; Sheila Tumilty; David Nunes
Journal:  Clin Infect Dis       Date:  2002-12-11       Impact factor: 9.079

View more
  45 in total

1.  Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.

Authors:  Andrew H Talal; Rositsa B Dimova; Randy Seewald; Raymond H Peterson; Marija Zeremski; David C Perlman; Don C Des Jarlais
Journal:  J Subst Abuse Treat       Date:  2012-03-08

2.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Alnoor Ramji; Marc Bilodeau; Stephen Wong; Jordan J Feld
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

3.  Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.

Authors:  Angelique Myles; Gerry J Mugford; Jing Zhao; Murray Krahn; Peizhong P Wang
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

4.  Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?

Authors:  Benedikt Fischer; Kate Kalousek; Jürgen Rehm; Jeff Powis; Mel Krajden; Jens Reimer
Journal:  Can J Public Health       Date:  2006 Nov-Dec

Review 5.  HIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and Treatment.

Authors:  Jenny Iversen; Kimberly Page; Annie Madden; Lisa Maher
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

6.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

7.  Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs.

Authors:  Jason Grebely; Sarah Larney; Amy Peacock; Samantha Colledge; Janni Leung; Matthew Hickman; Peter Vickerman; Sarah Blach; Evan B Cunningham; Kostyantyn Dumchev; Michael Lynskey; Jack Stone; Adam Trickey; Homie Razavi; Richard P Mattick; Michael Farrell; Gregory J Dore; Louisa Degenhardt
Journal:  Addiction       Date:  2018-08-28       Impact factor: 6.526

8.  Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.

Authors:  Gregory D Kirk; Jacquie Astemborski; Shruti H Mehta; Chuck Spoler; Cedric Fisher; Danisha Allen; Yvonne Higgins; Richard D Moore; Nezem Afdhal; Michael Torbenson; Mark Sulkowski; David L Thomas
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

9.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

10.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.